Craft

Alector

Stock Price

$5.9

2023-08-25

Market Capitalization

$494.6 M

2023-08-25

Revenue

$133.6 M

FY, 2022

Alector Summary

Company Summary

Overview
Alector is a biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. It offers AL001, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease.
Type
Public
Status
Active
Founded
2013
HQ
South San Francisco, CA, US | view all locations
Website
http://alector.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Arnon Rosenthal

    Arnon Rosenthal, Chief Executive Officer, Co-Founder and Director

  • Sara Kenkare-Mitra

    Sara Kenkare-Mitra, President and Head of Research and Development

  • Robert King

    Robert King, Chief Development Officer

  • Daniel Maslyar

    Daniel Maslyar, Vice President, Clinical Development, Oncology

Operating MetricsView all

Patent Applications

380
26.7%

FY, 2021

Patent Families

50
25.0%

FY, 2021

Product Candidates

4

FY, 2019

LocationsView all

1 location detected

  • South San Francisco, CA HQ

    United States

    131 Oyster Point Blvd #600

Alector Financials

Summary Financials

Revenue (Q2, 2023)
$56.2M
Net income (Q2, 2023)
$1.4M
Cash (Q2, 2023)
$131.5M
EBIT (Q2, 2023)
($3.6M)
Enterprise value
$404.0M

Footer menu